Cabaletta Bio
Steven Nichtberger, M.D., President and CEO Philadelphia, PA (NASDAQ: CABA)
President, Chief Executive Officer, and Co-Founder, Cabaletta Bio, Inc.
Search every verified Steven Nichtberger interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Steven Nichtberger, co-founder, president, and CEO of Cabaletta Bio, has been presenting the company’s progress in developing engineered T cell therapies for autoimmune diseases. He has described the company’s two parallel strategies: the CAAR T platform, targeting specific pathogenic B cells in diseases like pemphigus vulgaris and myasthenia gravis, and the CAR T strategy, led by the program CABA 201 for lupus and lupus nephritis. In 2023, Nichtberger highlighted that CABA 201’s IND was cleared by the FDA, citing published studies showing complete clinical responses in patients with lupus and myositis, and noted the product’s fully human binder and favorable safety profile observed in oncology settings. He also discussed an exclusive global licensing agreement with IASO for a CD19 binder used in CABA 201. Nichtberger has emphasized the company’s focus on achieving durable, potentially curative responses while minimizing side effects, contrasting their approach with broader immunosuppressive therapies. He has reported no dose-limiting toxicities in early cohorts of the Descartes trial for pemphigus vulgaris and described dose-dependent increases in CAR T persistence. He has also outlined plans for manufacturing partnerships, including with WuXi and Oxford Biomedica, and stated that the company’s cash runway extends to the end of the second quarter of 2024, with multiple clinical data catalysts expected across its programs.
Steven Nichtberger, M.D., President and CEO Philadelphia, PA (NASDAQ: CABA)
Steven Nichtberger has served as Chief Executive Officer, President, and Chairman of Cabaletta Bio since its founding in 2017. He is also a senior fellow and adjunct professor at the Wharton School of the University of Pennsylvania and a member of the executive committee of the board of governors of Main Line Health, a not-for-profit regional health system. In 2008, his leadership as founding CEO of Tengion (2004-2011) was recognized nationally with the prestigious Ernst & Young Entrepreneur of the Year® award for emerging companies. Earlier in his career, Dr. Nichtberger served as the head of…
Steven Nichtberger, M.D., President and CEO Philadelphia, PA (NASDAQ: CABA)
Steven Nichtberger, M.D., President, CEO, and Co-Founder Philadelphia, PA (NASDAQ: CABA)
A leadership call with Cabaletta Bio’s Co-Founder, CEO and Chairman Steven Nichtberger, MD and CMO David J. Chang, MD, MPH, FACR. Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune and alloimmune diseases. Cabaletta’s CAAR-T platform is supported by robust preclinical data and a clean safety profile seen so far in the clinic. Management will discuss the platform as well as supporting advancement of its lead program, DSG3-CAART, which is now dosing patients in the 3rd dose c…
Steven Nichtberger, M.D., President and CEO Philadelphia, PA (NASDAQ: CABA)
Steven Nichtberger, M.D., President, CEO and Co-Founder Philadelphia, PA (NASDAQ: CABA)
Sign in to search the full transcript archive, filter by topic, and access every quote from Steven Nichtberger.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans